These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 35843496)

  • 1. Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study.
    Bhatnagar T; Chaudhuri S; Ponnaiah M; Yadav PD; Sabarinathan R; Sahay RR; Ahmed F; Aswathy S; Bhardwaj P; Bilimale A; Kumar MS; Logaraj M; Narlawar U; Palanivel C; Patel P; Rai SK; Saxena V; Singh A; Thangaraj JW; Agarwal A; Alvi Y; Amoghashree ; Ashok P; Babu D; Bahurupi Y; Bhalavi S; Behera P; Biswas PP; Charan J; Chauhan NK; Chetak KB; Dar L; Das A; Deepashree R; Dhar M; Dhodapkar R; Dipu TS; Dudeja M; Dudhmal M; Gadepalli R; Garg MK; Gayathri AV; Goel AD; Gowdappa HB; Guleria R; Gupta MK; Islam F; Jain M; Jain V; Jawahar MLS; Joshi R; Kant S; Kar SS; Kalita D; Khapre M; Khichar S; Kombade SP; Kohli S; Kumar A; Kumar A; Kumar D; Kulirankal KG; Leela KV; Majumdar T; Mishra B; Misra P; Misra S; Mohapatra PR; Murthy MN; Nyayanit DA; Patel M; Pathania M; Patil S; Patro BK; Jalandra R; Rathod P; Shah N; Shete A; Shukla D; Shwethashree M; Sinha S; Sumana MN; Surana A; Trikha A; Tejashree A; Venkateshan M; Vijaykrishnan G; Wadhava S; Wig N; Gupta N; Abraham P; Murhekar MV
    Int J Infect Dis; 2022 Sep; 122():693-702. PubMed ID: 35843496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivated vaccine Covaxin/BBV152: A systematic review.
    Ahmed TI; Rishi S; Irshad S; Aggarwal J; Happa K; Mansoor S
    Front Immunol; 2022; 13():863162. PubMed ID: 36016940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Effectiveness of COVID-19 Vaccine and Identification of SARS-CoV-2 Variants among People Living with HIV on Highly Active Antiretroviral Therapy in Central Kerala of India-An Ambi-Directional Cohort Study.
    Thomas J; Rajmohan P; Jose P; Kannan R; Jose R; Uttumadathil Gopinathan U; Raphael L; Baiju NM; Krishna S; Attokaran T; Bency A T J; Venugopal A; Sheela S; Kallempadam A; Jose L; Innah SJ; Varghese PR; George A
    Viruses; 2023 Oct; 15(11):. PubMed ID: 38005865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Covid-19 Vaccines Available in India.
    Mukim M; Sharma P; Patweker M; Patweker F; Kukkar R; Patel R
    Comb Chem High Throughput Screen; 2022; 25(14):2391-2397. PubMed ID: 35293291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.
    Medigeshi GR; Batra G; Murugesan DR; Thiruvengadam R; Chattopadhyay S; Das B; Gosain M; Ayushi ; Singh J; Anbalagan A; Shaman H; Pargai K; Mehdi F; Das SJ; Kahlon N; Singh S; Kshetrapal P; Wadhwa N; Pandey AK; Bhatnagar S; Garg PK
    EBioMedicine; 2022 Apr; 78():103938. PubMed ID: 35305396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.
    Desai D; Khan AR; Soneja M; Mittal A; Naik S; Kodan P; Mandal A; Maher GT; Kumar R; Agarwal A; Gowda NR; H V; Kumar P; Pandey S; Pandey RM; Kumar A; Ray A; Jorwal P; Nischal N; Choudhary A; Brijwal M; Madan K; Lodha R; Sinha S; Dar L; Wig N; Guleria R
    Lancet Infect Dis; 2022 Mar; 22(3):349-356. PubMed ID: 34826383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the BBV-152 and AZD1222 vaccines among adult patients hospitalized in tertiary hospitals in Odisha with symptomatic respiratory diseases: A test-negative case-control study.
    Bhattacharya D; Kanungo S; Palo SK; Kshatri JS; Pattnaik M; Ghosal S; Mohapatra P; Rao CM; Sahoo A; Mishra RP; Mishra S; Mohanta AR; Doley C; Pati S
    Front Public Health; 2022; 10():1041586. PubMed ID: 36684990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India.
    Behera P; Singh AK; Subba SH; Mc A; Sahu DP; Chandanshive PD; Pradhan SK; Parida SP; Mishra A; Patro BK; Batmanabane G
    Hum Vaccin Immunother; 2022 Dec; 18(1):2034456. PubMed ID: 35321625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of prior vaccination with Covishield
    Abhilash KPP; Mathiyalagan P; Krishnaraj VRK; Selvan S; Kanagarajan R; Reddy NP; Rajendiran N; Hazra D; Gunasekaran K; Moorthy M; Jasmine S; Davis JP; George T; George K; Varghese GM; Rupali P; Barney Isaac TJ; Gupta R; Pichamuthu K; Joy M; Jayaseelan L; Mathews P; Peter JV
    Vaccine; 2022 Mar; 40(13):2107-2113. PubMed ID: 35168837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital.
    Arankalle V; Kulkarni-Munje A; Kulkarni R; Palkar S; Patil R; Oswal J; Lalwani S; Mishra AC
    Front Immunol; 2022; 13():928501. PubMed ID: 36211366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis.
    Contractor A; Shivaprakash S; Tiwari A; Setia MS; Gianchandani T
    PLoS One; 2022; 17(10):e0276759. PubMed ID: 36301977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breakthrough SARS-CoV-2 infections among BBV-152 (COVAXIN®) and AZD1222 (COVISHIELD
    Dash GC; Subhadra S; Turuk J; Parai D; Rath S; Sabat J; Rout UK; Kanungo S; Choudhary HR; Nanda RR; Pattnaik M; Pati S; Bhattacharya D
    J Med Virol; 2022 Mar; 94(3):1201-1205. PubMed ID: 34622961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibody responses to SARS-CoV-2 Omicron variants: Post six months following two-dose & three-dose vaccination of ChAdOx1 nCoV-19 or BBV152.
    Yadav PD; Sardana V; Deshpande GR; Shinde PV; Thangaraj JWV; George LS; Sapkal GN; Patil DY; Sahay RR; Shete AM; Joshi M; Murhekar M; Godbole S; Gupta N; Prakash S; Rathore M; Ujjainiya R; Singh AP; Mishra A; Dash D; Chaudhary K; Sengupta S;
    Indian J Med Res; 2024 Feb; 159(2):223-231. PubMed ID: 38517215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin.
    Kant R; Dwivedi G; Zaman K; Sahay RR; Sapkal G; Kaushal H; Nyayanit DA; Yadav PD; Deshpande G; Singh R; Chaowdhary S; Gupta N; Kumar S; Abraham P; Panda S; Bhargava B
    J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34652440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of ChAdOx1 nCoV-19 and BBIBP-CorV vaccines against COVID-19-associated hospitalisation and death in the Seychelles infected adult population.
    Theresa Pool SN; Shroff EH; Chetty A; Lewis L; Nonhlanhla YZ; Abdool Karim SS
    PLoS One; 2024; 19(4):e0299747. PubMed ID: 38578809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study.
    Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102424. PubMed ID: 35150961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variants of concern responsible for SARS-CoV-2 vaccine breakthrough infections from India.
    Singh UB; Rophina M; Chaudhry R; Senthivel V; Bala K; Bhoyar RC; Jolly B; Jamshed N; Imran M; Gupta R; Aggarwal P; Divakar MK; Sinha S; Arvinden VR; Bajaj A; Shamnath A; Jain A; ; Scaria V; Sivasubbu S; Guleria R
    J Med Virol; 2022 Apr; 94(4):1696-1700. PubMed ID: 34786733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN®) and ChAdOx1 nCoV-19 (COVISHIELD™) in seronegative and seropositive individuals in India: a multicentre, nonrandomised observational study.
    Asokan MS; Joan RF; Babji S; Dayma G; Nadukkandy P; Subrahmanyam V; Pandey A; Malagi G; Arya P; Mahajan V; Bhavikatti J; Pawar K; Thorat A; Shah P; Goud RB; Roy B; Rajukutty S; Immanuel S; Agarwal D; Saha S; Shivaraj A; Panikulam P; Shome R; Gulzar SE; Sharma AU; Naik A; Talashi S; Belekar M; Yadav R; Khude P; V M; Shivalingaiah S; Deshmukh U; Bhise C; Joshi M; Inbaraj LR; Chandrasingh S; Ghose A; Jamora C; Karumbati AS; Sundaramurthy V; Johnson A; Ramesh N; Chetan N; Parthiban C; Ahmed A; Rakshit S; Adiga V; D'souza G; Rale V; George CE; John J; Kawade A; Chaturvedi A; Raghunathan A; Dias M; Bhosale A; Raghu P; Shashidhara LS; Vyakarnam A; Bal V; Kang G; Mayor S
    Lancet Reg Health Southeast Asia; 2024 Mar; 22():100361. PubMed ID: 38482152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First and second doses of Covishield vaccine provided high level of protection against SARS-CoV-2 infection in highly transmissible settings: results from a prospective cohort of participants residing in congregate facilities in India.
    Tsundue T; Namdon T; Tsewang T; Topgyal S; Dolma T; Lhadon D; Choetso T; Woesal T; Yangkyi T; Gupta A; Peters D; Paster Z; Phunkyi D; Sadutshang TD; Chaisson RE; Dorjee K
    BMJ Glob Health; 2022 May; 7(5):. PubMed ID: 35609920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of COVID-19 Vaccination on Menstrual Cycle Patterns of Reproductive-age Women: A Multi-centric Observational Study.
    Kumar N; Gangane N; Mohapatra I; Rukadikar C; Sharmila V; Pushpalatha K; Eerike M; Santhoshi G; Samantaray SR; Seth S; Trigunait P; Reddy NJ; Patel S; Rani S; Mishra R; Negi K
    Curr Drug Res Rev; 2024; 16(2):237-248. PubMed ID: 37291775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.